Industry
Biotechnology
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Loading...
Open
70.43
Mkt cap
1.3B
Volume
89K
High
71.98
P/E Ratio
-7.82
52-wk high
86.93
Low
68.88
Div yield
N/A
52-wk low
18.09
Portfolio Pulse from
December 18, 2024 | 1:15 pm
Portfolio Pulse from
November 06, 2024 | 12:45 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 2:58 pm
Portfolio Pulse from Benzinga Newsdesk
September 26, 2024 | 12:14 pm
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 11:29 am
Portfolio Pulse from Benzinga Newsdesk
September 05, 2024 | 10:22 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.